As of 11/18/26
How We’ve Had Your Back and Amplified the Biotech Industry’s Voice
Since June, MassBio has made the case for biotech in Washington, on Beacon Hill, and with the investors and partners who back early-stage science. The goal throughout has been the same: making the U.S., and Massachusetts, the best place to start and grow a biotech company.
We expect to be even more engaged in the new year. Democrats will lead both the House and Senate, with new committee chairs, including Sens. Warren and Markey and Rep. Neal, and closer oversight of drug pricing and FDA. I’ve called on our Massachusetts delegation to lead on a competitiveness package for clinical trials, homegrown innovation, and domestic biomanufacturing. Our expanded federal policy team will make sure small and emerging companies are heard.
Does this make the U.S. a better place to build biotech? We ask that of every policy in Washington.
FDA & SEC

Made the case to FDA leadership in September, alongside two biotech CEOs, for keeping first-in-human trials in the U.S. We also commented on the Expedited IND Pilot, rallied members to apply, argued the case in BioSpace, and released our survey on trial offshoring.
On PDUFA VIII, we’re starting conversations with FDA and Congress to make sure faster, more predictable reviews reach sponsors of every size.(Comment Letter)
Convened biotech CEOs with SEC staff and formally backed letting public companies report twice a year instead of quarterly, cutting costs for small biotechs.
U.S.-China Competition

Sat down with Treasury officials in July, with biotech CEOs at the table, as they weighed adding biotech to outbound investment rules. Treasury’s October proposal includes biotech. Our case was, and continues to be, that restrictions must come with a real U.S. competitiveness agenda.
Our formal comments, due Dec. 7, are shaped by input from members.
Hosted House Select Committee on China staff in July to hear directly from small biotech CEOs about the Massachusetts ecosystem and competition from China.
Drug Pricing
Pressed CMS in August to do no harm as it writes Medicare negotiation into regulation (Comment Letter). That includes fair treatment for orphan drugs and clear rules for the small biotech pricing floor.
MassBio formally opposed Most Favored Nation pricing, and Congress has not taken up codifying it.
Early-stage biotech can’t survive on venture alone. We’re going after every other source of capital it needs.
Capital Access
Made the case in the Boston Globe, with Third Rock Ventures’ Abbie Celniker and Bob Tepper, that everyone, including investors, pharma, and government, must take on risk with academic spinouts and early-stage biotechs.
Connected more than 50 early-stage companies with funders at Align Summit.

Governor Healey and Secretary Paley came to MassBio to hear from dozens of early-stage biotech CEOs on access to capital and what the state can do to help startups grow here.
NIH Funding & Rules
Formally opposed OMB’s proposed rule that would add political appointee review to NIH grant decisions and make peer review advisory. Congress has barred OMB from finalizing it through mid-December, and we’re asking our delegation to make that protection permanent. (Comment)
We also told NIH how to measure impact: count the licenses, companies, and SBIR awards its research produces.
Drive Life Sciences

Announced a non-dilutive funding pool at Align, starting with $5 million of MassBio’s own over five years, and invited partners to join us.
Launched the Drive Industry Partner Network, with preferred pricing and startup-specific services worth potentially $250,000+ per company.
Since 2022, Drive has accelerated 70 companies that have raised $192 million and created nearly 100 jobs.
Massachusetts’ lead isn’t guaranteed. We’re working with the state to keep it.
State Policy
Conversations are underway on a public-private partnership to help Massachusetts keep pace and lead by example on clinical trials.
Helped keep upper payment limits out of the state budget, and backed both a biomarker testing amendment and Provider Choice amendment now in the House primary care bill.
Joined lawmakers, patients, and providers, in partnership with the Massachusetts Coalition for Action on Obesity, to press the state to restore obesity treatment coverage for MassHealth members and state employees.
Real Estate

Celebrated three companies betting on Massachusetts: Zealand Pharma’s new U.S. hub in Alewife, AstraZeneca’s $1 billion-plus R&D center in Kendall Square, and Madrigal’s new site in Waltham.
In Banker & Tradesman, asked the real estate community to partner with us so growing companies can put more dollars toward science and fewer toward difficult lease terms.
Talent & Leadership Pipeline
Termeer Ascend’s inaugural cohort of 15 rising leaders completed the program. Applications for the 2027 cohort open in January.
Nearly every graduate in Bioversity’s latest cohort had a job before graduation, in the entry-level roles members told us they struggle to fill.
If you’re not in the room, you’re not in the conversation. We make sure you’re there.
Media Engagement
- MassBio’s positions ran in the Wall Street Journal, Boston Globe, Endpoints, and Scrip on COINS, Massachusetts’ competitiveness, the Industry Snapshot, and FDA trial policy.
- BiotechTV’s CEO Conversations featured Rep. Jake Auchincloss; rare disease fathers Ilan Ganot (Solid Biosciences) and Daniel Fischer (Tevard Biosciences); and a look inside the Industry Snapshot.
Community & Visibility
- Released the 2026 Industry Snapshot, which found China’s drug pipeline grew 36% in a year and passed Europe’s, while the U.S. pipeline grew 0.6%.
- Took the small-biotech case to Capitol Hill in July, September, and October, hosted Sen. Ed Markey and Reps. Jake Auchincloss, Jim McGovern, and Stephen Lynch at our DC Reception, and relaunched the Federal Policy Working Group to meet quarterly in Washington.
- Brought patients and policymakers together. The Patient Advocacy Summit followed the patient journey from diagnosis to transplant and beyond, and legislators joined our Women’s Health Symposium on pancreatic cancer.
How to Engage
- Get to know our federal policy team. We built a dedicated federal function for small and emerging biotech, led by Ben Bradford and Nathan Dinh, our new Director of Federal Policy & Strategic Initiatives.
- Join our policy roundtables as they’re scheduled, both MassBio-only sessions and those we convene with policymakers and other outside partners. Reach out to Nathan to be on the short list.
- Answer our surveys promptly. Your responses shape MassBio’s policy goals and the data we bring into meetings with lawmakers, including our work on FDA and COINS this fall.
- Follow Kendalle and MassBio on LinkedIn and engage with our posts.
- Check your email subscriptions and settings so our updates reach you.